Calculus Venture Capital Research
Investment Thesis
Calculus Venture Capital is a San Mateo, California deep-tech investment firm launched in May 2025 by Swati Chaturvedi, who coined the term "deep technology" in 2013 and previously built the Propel(x) syndication platform (portfolio raised $1.5B+, with a notable IPO exit in Smoltek). Calculus VC operates under the belief that we are entering a "Deeptech Century" driven by advances in AI, quantum computing, and programmable biology. The firm organizes its thesis around three pillars: the Future of Computing and AI (new compute materials, quantitative/physical-world AI, immersive and neural interfaces), Computational Life Sciences and HealthTech (AI-first therapeutics and discovery platforms, programmable-biology infrastructure, personalized/continuous care), and Advanced Industrial Technologies (AI and automation in industry, land/ocean/space transport and communications, resource efficiency). A distinguishing feature of Calculus VC's approach, relative to earlier-stage deeptech funds, is that it requires scientific proof-of-concept before investing — a functional prototype or initial commercial traction — rather than backing pure science projects pre-validation.
Stage Focus
Calculus VC invests at Series A and Series B. This is corroborated independently by the firm's LinkedIn company page and by third-party investor guides (Superscout), both of which describe the fund as focused on startups that have already cleared scientific proof-of-concept and are ready to scale, rather than pre-seed or seed deeptech bets.
Check Size
No specific check-size range is publicly disclosed. Observed behavior across the firm's two confirmed 2026 investments (Trailhead Biosystems, CloudNC) shows Calculus VC writing checks as part of larger syndicates alongside a lead investor, rather than disclosing a standalone ticket size.
Lead Tendency
Calculus VC follows rather than leads. In both disclosed 2026 investments, another firm held the lead position: MAK Capital led Trailhead Biosystems' round (Calculus joined as a syndicate participant), and Nimble Ventures led CloudNC's $20M Series B extension (Calculus VC, Entrepreneur First, and LM Ventures participated alongside Lockheed Martin's venture arm).
Recent Activity
The fund held its first close in late 2025 and is actively deploying from Calculus Fund I. Two investments have been publicly confirmed in 2026: Trailhead Biosystems (announced late August 2026, a Cleveland Clinic/Case Western spinout building an AI- and robotics-driven cell-differentiation platform for drug discovery and cell therapy) and CloudNC (announced September 2026, an AI-powered CAM/manufacturing software company, via a $20M Series B extension led by Nimble Ventures). SimBioSys, an AI-powered breast-cancer surgical-planning company (TumorSight Viz), is also a confirmed portfolio company as of an April/May 2026 ASBrS conference showcase, though the specific investment date was not disclosed. The firm has also been active in community-building, co-hosting an investor/founder dinner with Morgan Stanley Private Wealth Management in Palo Alto (September 2026), and GP Swati Chaturvedi is scheduled to moderate the Physical AI and Robotics panel at the 10th Annual MIT AI Conference on October 17, 2026.
Portfolio Highlights
Confirmed portfolio companies are Trailhead Biosystems (trailbio.com), SimBioSys (simbiosys.com), and CloudNC (cloudnc.com). Given the fund's May 2025 founding and recent first close, the portfolio is still small and forming; no exits have been disclosed for Calculus Fund I itself. Note that Healx, an AI drug-discovery company that GP Swati Chaturvedi backed in 2022 with three drug candidates now in Phase 2 trials, was a Propel(x) syndicate deal predating Calculus VC's founding and is not a Calculus Fund I portfolio company — it is referenced here only as evidence of the GP's pre-fund track record in AI-driven biotech.
Team
- Swati Chaturvedi, General Partner / Managing Partner — Coined the term "deep technology" in 2013; founded MIT Angels; CEO and co-founder of Propel(x), a deeptech syndication platform whose collective portfolio raised over $1.5B; MBA from MIT Sloan, M.S. from MIT and UC Berkeley, degree from University of Roorkee (IIT Roorkee), India. Recognized with a World Technology Award (2016) and named an Inspiring Fintech Female (2021) and one of the Bay Area's Most Influential Women (2021).
- Jason May, Technical Due Diligence — Leads technical evaluation of prospective investments.
- Hasmita Kapoor, Marketing & Operations — Oversees the firm's marketing and operational functions.
- Vincent Granville, Advisor — Provides advisory support; also associated with bondingAI.
Decision Process
Calculus VC functions as a solo-GP-led firm: Swati Chaturvedi is the sole General Partner and investment decision-maker, supported by a small team handling technical diligence, marketing/operations, and advisory input rather than co-equal investment partners.
Founder Preferences
Calculus VC favors scientist-founder teams paired with an experienced operating executive — for example, Trailhead Biosystems' scientist-founder Dr. Jan Jensen alongside CEO David Llewellyn, described by the firm as "the perfect executor" with prior industry experience. The firm places heavy weight on defensible, hard-to-replicate science (e.g., proprietary datasets, novel experimental methods) combined with a credible path to commercial traction.
Geographic Focus
Primarily the United States, consistent with the firm's San Mateo, California headquarters and Silicon Valley/Bay Area network (Propel(x), MIT Angels).
Fund Details
Calculus VC is currently deploying its debut vehicle, Calculus Fund I, which held its first close in late 2025 after Chaturvedi launched the firm in May 2025. Third-party investor-list sources (repeated across multiple LinkedIn "solo GP" roundups) cite a fund size around $75M, though this figure is not confirmed on the firm's own site and should be treated as moderate-confidence. The firm has 2-10 employees per its LinkedIn profile.